MPL and Thrombocytopenia: As expected based on the selinexor profile [20], SDd had higher rates of thrombocytopenia, although the risk of concomitant bleeding was very low (one case, 2.9%), and nearly all cases were reversible and manageable using dose modifications along with appropriate supportive care including a thrombopoietin receptor agonist such as romiplostim [34].